Compare Biogen Inc (BIIB) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Starbucks Corp — how do they compare? Biogen Inc trades at $190 (market cap $28.34B), while Starbucks Corp trades at $105.55 (market cap $121.00B). The key difference: Starbucks Corp is far larger — about 4.3× Biogen Inc's market cap, and Starbucks Corp pays a 2.34% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SBUX | |
|---|---|---|
Market Cap | $28.34B | $121.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $107.34 |
52-Week Low | $122.68 | $78.46 |
Enterprise Value | $30.62B | $143.69B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Starbucks (SBUX) trades at $107.34, up 1.25% on the day, with a bullish technical signal from moving averages and near the consensus price target of $108.31. Recent Q2 2026 results showed revenue of $9.53B and EPS beat expectations, while the company focuses on cost-cutting through AI initiatives. The stock exhibits strong support at $107 and faces resistance at $108.
The outlook is cautiously optimistic with analyst consensus leaning buy (47.46%), but high P/E of 81.94 and declining net income margins pose valuation concerns. Key risks include execution of AI cost savings and competitive pressures, while dividend growth and loyalty program strength offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
